Biotech Values

[sodrock]

“We believe that MNTA’s technology will enable us
to uniquely demonstrate equivalence to innovative
products. Out intent is to develop FoB’s that are
not simply biosimilar but have the potential to be
biogenerics, interchangeable and substitutable
for the branded biologics.”
—Craig Wheeler, CEO (from 2/14/08 CC)

I just had to re-post this for all to see. They accomplished this in a BIG way with Menox... SNY was totally baffled that they were able to get FDA approval for Menox as an interchangeable product. Again this is so key as to why TEVA is dead in the water with their version.. So very very important.